www.fdanews.com/articles/75412-nektar-in-pact-to-acquire-aerogen
NEKTAR IN PACT TO ACQUIRE AEROGEN
August 16, 2005
Nektar Therapeutics said Monday it signed a definitive agreement to acquire Aerogen Inc. in a deal worth about $32 million. Nektar (NKTR: news, chart, profile) , a San Carlos, Calif.-based drug-delivery developer, said it will pay $8 million in cash and about $24 million in stock, while retaining the option of paying the full buyout price in cash. Common shares of Aerogen (AEGN: news, chart, profile) are traded on the pink sheets. Under the terms of the deal, each Aerogen common share will be exchanged for about 75 cents per share, while each Aerogen A-1 preferred share will be exchanged for approximately $29.03 a share.